Background-Lipoproteins containing apolipoprotein (apo) CIII predict coronary heart disease and associate with components of the metabolic syndrome. ApoCIII inhibits lipoprotein catabolism in plasma. However, it is unknown whether apoCIII itself, or in association with VLDL, LDL, or HDL, directly affects atherogenic mechanisms in vascular cells. Thus, we investigated the direct effect of lipoproteins that do or do not have apoCIII, and apoCIII itself, on adhesion of THP-1 cells, a human monocytic cell line, to vascular endothelial cells (ECs).
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Alaupovic and colleagues 5, 6 proposed that apoB lipoproteins that have apoCIII would have distinct metabolism and relationships to atherosclerosis compared with those that do not have apoCIII and found that the concentration of apoCIII containing lipoproteins correlates with the progression of coronary atherosclerosis. We reported that the plasma concentration of apoCIII in apoB lipoproteins and the apoB concentration of LDL particles that have apoCIII independently predict risk of coronary heart disease (CHD). 7, 8 ApoB lipoproteins with apoCIII appear to augment risk out of proportion to their low concentration in plasma, eg, 50 to 100 g apoB/mL. Thus, we hypothesized that apoCIII-containing lipoproteins have enhanced atherogenicity relative to their counterparts that do not contain apoCIII.
The adhesion of circulating monocytes to endothelial cells (ECs) contributes importantly to the inflammatory aspects of atherogenesis. Monocytes from hypercholesterolemic patients have increased expression of integrins and other adhesion molecules 9, 10 and show increased adhesion to ECs in vitro. 9 In this regard, we previously reported that remnant lipoproteins (RLPs) induced U937 monocytic cells to adhere to ECs. 11 Because RLPs have a high content of apoCIII, 12 we hypothesized that apoCIII may be involved in this process.
The present study tested the hypothesis that apoB lipoproteins with apoCIII induce monocyte activation and subsequent adhesion to ECs. It also examined the direct effects of apoCIII on signal transduction involved in these processes.
Methods

Cell Culture and Reagents
THP-1 cells, a human monocytic cell line, were obtained from American Type Culture Collection. Human saphenous vein ECs (HSVECs) (passage 3) and human peripheral monocytes were collected under a protocol approved by the Human Research Committee of the Brigham and Women's Hospital and cultured as described previously. 11 Human apoCI, apoCII, apoCIII, and apoE were purchased from Academy Biomedical. Antibodies used in the present study include mouse anti-␤1-integrin antibody (JB1A) (Chemicon International); mouse anti-activated ␤1-integrin antibody (B44) (Chemicon International); mouse anti-VCAM-1 (C3P4) (Chemicon International); mouse anti-ICAM-1 (P2A4) (Chemicon International); mouse anti-PKC␣ antibody (BD Biosciences); mouse anti-PKC␤ antibody (BD Biosciences); goat anti-PKC␦ antibody (Chemicon International); rabbit anti-PKC antibody (Upstate); mouse anti-RhoA monoclonal antibody (Santa Cruz Biotechnology); goat anti-apoCI, anti-apoCII, anti-apoCIII, and anti-apoE antibody (Academy Biomedical); and mouse anti-HLA class I monoclonal antibody (W6/32) (American Type Culture Collection).
Lipoprotein and Lipid Preparation
Blood was drawn in tubes containing EDTA from 18 healthy volunteers after a 12-hour fast. The study was approved by the Institutional Review Board of Harvard School of Public Health. The subjects were not taking cardiovascular medications, antioxidants, or estrogen. Immunoaffinity chromatography was conducted with affinity-purified anti-human apoCIII on Sephrose4B resin (apoCIII resin) (Academy Biomedical) to separate the plasmas into a lipoprotein fraction with (CIII ϩ ) and one without (CIII Ϫ ) apoCIII. VLDL (dϽ1.006), LDL (1.006ϽdϽ1.050), and HDL (1.063ϽdϽ1.210) were isolated from 2 lipoprotein fractions (CIII ϩ , CIII Ϫ ) by very-fast ultracentrifugation with an Optima TLX ultracentrifuge (Beckman Coulter) as described previously. 8 The lipid fraction of a lipoprotein preparation was extracted with chloroform and methanol, dried under N 2 gas, and stored in dimethyl sulfoxide before use. To evaluate the effect of apoCIII, we incubated VLDL CIII Ϫ or LDL CIII Ϫ with apoCIII (100 g/mL) for 2 hours at 37°C and reisolated them by ultracentrifugation. 13, 14 Endotoxin levels in the lipoprotein fractions measured with a Limulus amebocyte lysate chromogenic test (Associates of Cape Cod) were Ͻ0.03 EU/mL.
Lipid and Apolipoprotein Measurements
Cholesterol was determined in plasma and lipoprotein preparations enzymatically, and apoB and apoCIII were determined by ELISA as described previously. 8 The molecular ratio of apoCIII to apoB of lipoprotein preparations that reflects apoCIII enrichment on the particles was calculated by using their respective molecular mass (apoB, 550 kDa; apoCIII, 8.8 kDa).
Adhesion Assay
Static Conditions
The HSVEC monolayer in a 96-well plate was stimulated with IL-1␤ (10 ng/mL) (Genzyme) for 4 hours before the adhesion assay was begun. THP-1 cells (1ϫ10 6 /mL) were labeled with BCECF-AM (Calbiochem), placed on an HSVEC monolayer (6 wells per condition) at 1ϫ10 5 THP-1 cells per well, and allowed to adhere for 10 minutes. After nonadherent cells were removed, the fluorescent intensity of adhered cells and that of total cells applied to the well was measured by CytoFlour II (Perceptive Biosystems). The ratio of adherent to total cells was expressed as adhesion (percent).
Flow Conditions
Adhesion experiments used a parallel-plate flow chamber, as previously described. 15 Briefly, confluent HSVEC monolayers, grown on 25-mm glass coverslips (Carolina Biological Supply) and coated with 5 g/mL fibronectin (Sigma), were stimulated with IL-1␤ (10 ng/mL) for 4 hours and inserted into the flow chamber. THP-1 cells (0.5ϫ10 6 /mL) suspended in flow buffer (PBS/0.1% human serum albumin) were drawn through the chamber at decreasing flow rates corresponding to an estimated shear stress of 1.0, 0.76, and 0.5 dyne/cm 2 . THP-1 cell interaction was determined after the initial minute of each flow rate by counting the number of adherent cells in Figure 1 . VLDL CIII ϩ and LDL CIII ϩ induce the adhesion of THP-1 cells to ECs. A, THP-1 cells were incubated in the presence of indicated lipoproteins (100 g apoB/mL) or PBS (control) for 8 hours, and static adhesion assays were carried out. *PϽ0.01 vs control; #PϽ0.01 vs VLDL CIII Ϫ or LDL CIII Ϫ . B, THP-1 cells were incubated with indicated concentrations of VLDL CIII ϩ or LDL CIII ϩ for 8 hours, and static adhesion assays were carried out. *PϽ0.05, **PϽ0.01 vs 0 g apoB/mL. Data are representative of 6 independent experiments with similar results. C, Human peripheral monocytes were incubated in the presence of the indicated lipoproteins (100 g apoB/mL), apoCIII (100 g/mL), or PBS (control) for 8 hours, and static adhesion assays were carried out. 
Flow Cytometry
THP-1 cells (1ϫ10 6 /mL) were treated with mouse anti-␤1-integrin antibody (JB1A) or mouse anti-activated ␤1-integrin antibody (B44) for 10 minutes, followed by incubation with FITC-conjugated goat anti-mouse antibody. Cell surface (activated) ␤1-integrin expression was analyzed with a FACS Caliber (BD Biosciences).
Immunoblotting
Total cell lysates and the membrane fraction of THP-1 cells (1ϫ10 6 /mL) were prepared as described previously. 16 An equal amount of protein (10 g) from each fraction was subjected to 12% SDS-PAGE. The activation of RhoA and PKC was examined by detecting the membrane-bound protein that translocated from cytosol fraction with an ECL Plus (Amersham Biosciences, Piscataway, NJ). Blots were quantified by densitometry, and the membrane-associated fraction was expressed as percent of total.
Rho Pull-Down Assay
Rho pull-down assay was carried out with a Rho activation kit (Pierce) following the manufacturer's protocol. In brief, total cell lysates of THP-1 cells ( 1ϫ10 7 ) were incubated with 400 g Rhotekin-RBD (Rho-binding domain) to collect the activated form of RhoA. The activated RhoA was detected with an anti-RhoA antibody.
Quantification of F-actin in THP-1 Cells
THP-1 cells were fixed with 3.7% formaldehyde in PBS, made permeable with 0.1% Triton-X100 in PBS, and stained with FITCphalloidin. F-actin content was measured with CytoFlour II.
Statistical Analysis
Adhesion assay data are presented as meanϮSEM. Data were analyzed using ANOVA, with a value of PϽ0.05 considered significant.
Results
VLDL CIII ؉ and LDL CIII ؉ Induce the Adhesion of THP-1 Cells and Human Peripheral Monocytes to ECs
Treatment with VLDL CIII ϩ or LDL CIII ϩ , but not with VLDL CIII Ϫ or LDL CIII Ϫ , significantly increased the adhesion of THP-1 cells to ECs ( Figure 1A ). Adhesion of THP-1 cells to ECs increased in a concentration-dependent manner up to 100 g apoB/mL ( Figure 1B ). Adhesion significantly increased as early as 4 hours after incubation and reached a A, THP-1 cells were incubated in the presence of indicated concentrations of apoCIII for 8 hours, and static adhesion assays were carried out. *PϽ0.05, **PϽ0.01 vs 0 g/mL. B, THP-1 cells were incubated in the presence of indicated lipoproteins (100 g apoB/mL) or PBS (control) for 8 hours, and static adhesion assays were carried out. The molecular ratio of apoCIII to apoB in lipoprotein preparations was calculated as in Methods. *PϽ0.01 vs control; #PϽ0.05 vs VLDL CIII Ϫ or LDL CIII Ϫ . C, VLDL CIII ϩ , LDL CIII ϩ , or apoCIII was pretreated in the presence or absence of indicated antibodies (50 g/mL) for 30 minutes; then, THP-1 cells were incubated in the presence of the treated or untreated VLDL CIII ϩ , LDL CIII ϩ (100 g apoB/mL), or apoCIII, or PBS (control) for 8 hours, and static adhesion assays were carried out. *PϽ0.01 vs control; #PϽ0.05 vs VLDL CIII ϩ , LDL CIII ϩ , or apoCIII without antibodies. Data are representative of 4 independent experiments with similar results. D, Linear regression between THP-1 cell adhesion under static conditions (%) and the molecular ratio of apoCIII to apoB. Data points represent adhesion assays of 12 VLDL CIII ϩ samples (ⅷ) and 11 LDL CIII ϩ samples (⅙). maximum at 8 hours after incubation. Therefore, subsequent experiments incubated THP-1 cells with lipoproteins at 100 g apoB/mL for 8 hours before the adhesion assay. VLDL CIII ϩ or LDL CIII ϩ also increased the adhesion of human peripheral blood monocytes to ECs ( Figure 1C ).
ApoCIII Mediates VLDL CIII
؉ and LDL CIII ؉ -Induced THP-1 Cell Adhesion to ECs
ApoCIII treatment of THP-1 cells (Figure 2A ) or human peripheral blood monocytes ( Figure 1C ) significantly induced their adhesion to ECs, whereas apoCI, apoCII, and apoE had no effect (data not shown). Next, we added apoCIII to VLDL CIII Ϫ or LDL CIII Ϫ and reisolated the VLDL and LDL by ultracentrifugation. The molecular ratios of apoCIII to apoB of VLDL CIII ϩ (VLDL CIII Ϫ ϩapoCIII) and LDL CIII ϩ (LDL CIII Ϫ ϩapoCIII), formed in vitro, were Ϸ30% of native VLDL CIII ϩ and LDL CIII ϩ . VLDL CIII ϩ , formed in vitro, enhanced THP-1 cell adhesion, although to a lesser extent compared with native VLDL CIII ϩ . Reconstituted LDL CIII ϩ only slightly increased THP-1 cell adhesion, probably because of low apoCIII enrichment (molecular ratio of apoCIII to apoB, 2.7) ( Figure 2B ). Preincubation of VLDL CIII ϩ or LDL CIII ϩ with anti-apoCIII significantly reduced their effects on THP-1 cell adhesion. In contrast, anti-apoCI, anti-apoCII, and anti-apoE antibodies did not affect their ability to induce THP-1 cell adhesion. Furthermore, anti-apoCIII also completely inhibited apoCIII-induced THP-1 cell adhesion ( Figure 2C ). These results indicate that apoCIII in these lipoprotein fractions induces the enhancement of THP-1 cell adhesion. Adhesion of THP-1 cells incubated with VLDL CIII ϩ or LDL CIII ϩ significantly correlated with the molecular ratio of apoCIII/ apoB of these lipoproteins ( Figure 2D ).
VLDL CIII ؉ , LDL CIII ؉ , and ApoCIII Induce the Adhesion of THP-1 Cells to ECs Under Flow Conditions
ApoCIII or VLDL CIII ϩ treatment of THP-1 cells significantly increased their adhesion to ECs at each level of fluid shear examined ( Figure 3A) . LDL CIII ϩ also significantly increased THP-1 cell adhesion, although to a lesser extent. VLDL CIII Ϫ or LDL CIII Ϫ did not affect THP-1 cell adhesion. Strikingly, THP-1 cells treated with apoCIII alone or in combination with VLDL or LDL showed a distinct function compared with control cells. Firm adhesion makes up 90% to 95% of the EC interactions of treated THP-1 cells, whereas rolling interactions were minimal ( Figure 3B ; see also the online Data Supplement for video clip). In contrast, Ϸ40% of the interactions of control THP-1 cells not exposed to apoCIII were rolling, and 60% were firmly adhered. Because an increase in leukocyte arrest under shear flow would require integrin activation, 15, 17 these data suggest that THP-1 cell integrins become activated after treatment with apoCIII.
VLDL CIII
؉ and LDL CIII ؉ Activate ␤1-Integrin in THP-1 Cells
In vivo 18 and in vitro studies, including ours, 11 have shown a major role for ␤1-integrin in firm adhesion of monocytes to vascular endothelium. We therefore examined whether VLDL CIII ϩ or LDL CIII ϩ affects the expression or activity of ␤1-integrin in THP-1 cells using flow cytometry. Treatment with VLDL CIII ϩ , LDL CIII ϩ , or apoCIII alone increased the active forms of ␤1-integrin in THP-1 cells with a slight increase in total ␤1-integrin expression, indicating that they induced ␤1-integrin activation ( Figure 4A ). VLDL CIII Ϫ or LDL CIII Ϫ had no effect. Binding-blocking ␤1-integrin antibody (JB1A) abolished THP-1 cell adhesion induced by VLDL CIII ϩ , LDL CIII ϩ , or apoCIII ( Figure 4B ). Pretreatment of ECs with anti-VCAM-1 antibody, but not anti-ICAM-1 antibody, reversed the effects of VLDL CIII ϩ , LDL CIII ϩ , and apoCIII on THP-1 cell adhesion ( Figure 4C ), suggesting that apoCIII induces THP-1 adhesion by inducing ␤1-integrin and its consequent binding to its cognate ligand VCAM-1.
؉ and LDL CIII ؉ Activate RhoA in THP-1 Cells
RhoA plays a crucial role in the migration and adhesion of monocytes by increasing the expression and/or binding affinity of cell surface integrins. Treatment of THP-1 cells with VLDL CIII ϩ , LDL CIII ϩ , or apoCIII caused RhoA translocation to the membrane, an indicator of activation ( Figure  5A ), and increased the active form of RhoA in THP-1 cells ( Figure 5B) , whereas VLDL or LDL CIII Ϫ had no effect. Pretreatment with C3 exoenzyme, a specific RhoA inhibitor, partially inhibited ␤1-integrin activation and THP-1 cell adhesion induced by VLDL CIII ϩ , LDL CIII ϩ , or apoCIII ( Figure 5C, 5D ). ApoCIII and VLDL CIII ϩ or LDL CIII ϩ increased F-actin content in THP-1 cells, indicating rearrangement of actin cytoskeleton by RhoA ( Figure 5E ). . VLDL CIII ϩ and LDL CIII ϩ activate ␤1-integrin in THP-1 cells. A, THP-1 cells were treated with indicated lipoproteins (100 g apoB/mL), apoCIII (100 g/mL), or PBS (control) for 8 hours. Cell surface ␤1-integrin or activated ␤1-integrin was detected by flow cytometry. B, THP-1 cells were pretreated in the presence of w6/32 or JB1A (50 g/mL) for 30 minutes and then incubated in the presence of VLDL CIII ϩ , LDL CIII ϩ (100 g apoB/mL), apoCIII (100 g/mL), or PBS (control) for 8 hours before adhesion assay. *PϽ0.01 vs control; #PϽ0.05 vs VLDL CIII ϩ , LDL CIII ϩ , or apoCIII without antibodies. C, THP-1 cells were incubated in the presence of VLDL CIII ϩ , LDL CIII ϩ (100 g apoB/mL), apoCIII (100 g/mL), or PBS (control) for 8 hours. ECs were pretreated in the presence or absence of indicated antibodies (50 g/mL) for 30 minutes before adhesion assay. Figure 6A ). VLDL CIII ϩ or LDL CIII ϩ did not activate PKC (data not shown). ApoCIII alone also activated PKC␣, and PKC␤ to a lesser extent, but did not affect PKC␦. Thus, we examined whether PKC␣ mediates ␤1-integrin activation and, in turn, THP-1 cell adhesion to ECs. Pretreatment with Go6976, a selective PKC␣ inhibitor, inhibited ␤1-integrin activation induced by VLDL CIII ϩ , LDL CIII ϩ , or apoCIII ( Figure 6B ). Go6976 partially inhibited RhoA activation ( Figure 6C ). In contrast, C3 did not affect PKC␣ activation by these preparations (data not shown), indicating that RhoA activation is dependent on PKC␣. In accord with PKC inhibition, Go6976 significantly inhibited THP-1 cell adhesion induced by VLDL CIII ϩ , LDL CIII ϩ , or apoCIII ( Figure 6D ). Anti-apoCIII antibody inhibited PKC␣ activation induced by VLDL CIII ϩ , LDL CIII ϩ , or apoCIII ( Figure 6E ). These results indicate that PKC␣ activation by VLDL CIII ϩ or LDL CIII ϩ depends on apoCIII in these particles.
Effects of Lipids of VLDL CIII ؉ and LDL CIII ؉ on PKC Activation and THP-1 Cell Adhesion to ECs
Lipids of VLDL CIII ϩ and LDL CIII ϩ had minimal effects on THP-1 cell adhesion ( Figure 7A ). Although LDL CIII ϩ lipid activated PKC␦ in THP-1 cells (Figure 7B ), rottlerin, a specific PKC␦ inhibitor, did not reduce LDL CIII ϩ -induced THP-1 cell adhesion ( Figure 7C ). Thus, PKC␦ does not appear to mediate the effect of LDL CIII ϩ on THP-1 cell adhesion.
Effects of HDL CIII ؉ and HDL CIII ؊ on THP-1 Cell Adhesion to ECs
In static adhesion assays, HDL CIII Ϫ at 500 g cholesterol/mL significantly reduced THP-1 cell adhesion by 27% (PϽ0.01). HDL CIII ϩ did not reduce adhesion ( Figure 8A ). In flow Figure 5 . VLDL CIII ϩ and LDL CIII ϩ activate RhoA in THP-1 cells. A, THP-1 cells were incubated in the presence of indicated lipoproteins (100 g apoB/mL), apoCIII (100 g/mL), or PBS (control) for 2 hours, and the membrane and total RhoA protein was detected with immunoblotting. B, THP-1 cells were incubated in the presence of indicated lipoproteins (100 g apoB/mL), apoCIII (100 g/mL), or PBS (control) for 2 hours. Rhotekin-bound RhoA was detected as active RhoA with immunoblotting. C, D, THP-1 cells were pretreated in the presence or absence of C3 exoenzyme (C3) (10 g/mL) for 30 minutes and then incubated in the presence of VLDL CIII ϩ , LDL CIII ϩ (100 g apoB/ mL), apoCIII (100 g/mL), or PBS (control) for 8 hours. Cell surface-activated ␤1-integrin was detected by flow cytometry (C), or static adhesion assay was carried out (D). *PϽ0.01 vs control; #PϽ0.05 vs VLDL CIII ϩ , LDL CIII ϩ , or apoCIII without C3 exoenzyme. E, THP-1 cells were incubated in the presence of indicated lipoproteins (100 g apoB/mL), apoCIII (100 g/mL), or PBS (control). Their F-actin content was examined as in Methods and is expressed as percent of control. Data are representative of 4 independent experiments with similar results.
adhesion assays, HDL CIII Ϫ tended to decrease THP-1 cell adhesion at a shear stress of 1.0 dyne/cm 2 (Pϭ0.09) but not at lower shear rates. HDL CIII ϩ did not affect THP-1 cell adhesion under flow conditions ( Figure 8B ).
Discussion
ApoCIII independently predicts CHD. 7, 8 Excessive apoCIII on apoB lipoproteins delays their lipolysis 2 and inhibits their uptake by normal, high-affinity receptors on hepatocytes. 3 However, direct effects on vascular cells of apoB lipoproteins with apoCIII specifically or apoCIII itself remain untested. We found that VLDL or LDL particles that contain apoCIII, but not those that do not, increase the adhesion of monocytic cells to ECs under both static and flow conditions. ApoCIII itself rather than other apolipoproteins or lipids in the particles caused this proadhesive effect. Proadhesive concentrations of apoCIII-containing lipoproteins, 50 to 100 g apoB/mL, are well within the range found in fasting plasma, eg, 50 g apoB/mL in normolipidemic persons and Ͼ100 g apoB/mL in hypertriglyceridemic persons or those with CHD. 8, 19 Because apoCIII-containing lipoproteins also contain other apolipoproteins such as apoCI, apoCII, and apoE, 20 as well as various lipids, we performed experiments that localized the proadhesive effect to apoCIII itself. First, apoCIII itself enhanced THP-1 cell adhesion in a concentration range of human plasma, ie, 20 to 100 g/mL. ApoCI, apoCII, or apoE did not increase adhesion. Second, apoCIII added in vitro to VLDL that did not have apoCIII in vivo conferred a proadhesive property to the VLDL. Third, antibodies against apoCIII, but not against apoCI, apoCII, or apoE, decreased the proadhesive effect. Fourth, the number of apoCIII molecules per VLDL or LDL particle strongly correlated with extent of adhesion. Finally, lipids extracted from apoCIIIcontaining VLDL or LDL did not increase adhesion. Thus, apoCIII itself, but not other apolipoproteins that commonly cluster with apoCIII on apoB lipoproteins or lipoprotein lipids, mediates the enhanced THP-1 cell adhesion to ECs. The effect of LDL CIII ϩ was smaller than that of VLDL CIII ϩ , probably because it has fewer apoCIII molecules per particle.
Under flow conditions, THP-1 cells interact with ECs by either rolling or firm adhesion. Firm adhesion occurs after a Figure 6 . VLDL CIII ϩ and LDL CIII ϩ activate PKC in THP-1 cells. A, THP-1 cells were incubated in the presence of indicated lipoproteins (100 g apoB/mL), apoCIII (100 g/mL), or PBS (control) for 2 hours, and the membrane and total PKC isoform protein was detected with immunoblotting. B, THP-1 cells were pretreated in the presence or absence of Go6976 (Go) (5 nmol/L) for 30 minutes and then incubated in the presence of VLDL CIII ϩ , LDL CIII ϩ (100 g apoB/mL), apoCIII (100 g/mL), or PBS (control) for 8 hours. Then, cell surface-activated ␤1-integrin was detected by flow cytometry. C, THP-1 cells were pretreated in the presence or absence of Go6976 (5 nmol/L) for 30 minutes and then incubated in the presence of VLDL CIII ϩ , LDL CIII ϩ (100 g apoB/mL), apoCIII (100 g/mL), or PBS (control) for 2 hours. The membrane and total RhoA protein was detected with immunoblotting. D, THP-1 cells were pretreated in the presence or absence of Go6976 (5 nmol/L) for 30 minutes and then incubated in the presence of VLDL CIII ϩ , LDL CIII ϩ (100 g apoB/mL), apoCIII (100 g /mL), or PBS (control) for 8 hours. *PϽ0.01 vs control; #PϽ0.05 vs VLDL CIII ϩ , LDL CIII ϩ , or apoCIII without Go6976. E, VLDL CIII ϩ , LDL CIII ϩ (100 g apoB/mL), or apoCIII (100 g /mL) was pretreated in the presence or absence of apoCIII antibody (50 g/mL) for 30 minutes; then, THP-1 cells were incubated in the presence of the treated or untreated VLDL CIII ϩ , LDL CIII ϩ (100 g apoB/mL), or apoCIII, or PBS (control) for 2 hours. Data are representative of 4 independent experiments with similar results.
rolling phase. ApoCIII treatment strongly promoted firm adhesion. Thus, apoCIII may reduce THP-1 cell rolling time before firm adhesion to ECs, may increase the percentage of rolling interaction that converts to firm adhesion, or perhaps may eliminate the rolling phase in some interactions.
We then investigated the intracellular mechanism(s) that mediate THP-1 interactions with ECs. We previously reported that RLPs induced U937 cell adhesion via activation of ␤1-integrin 11 and that inactivation of ␤1-integrin by atorvastatin 11 or amlodipine 21 reduced THP-1 cell adhesion to ECs. ␤1-Integrin is expressed on monocytes, on lymphocytes, and at a low level on neutrophils and supports firm adhesion to VCAM-1 on activated endothelium. 17 Blockade of ␤1-integrin reduced monocyte adhesion and atherosclerotic lesion formation in apoE Ϫ/Ϫ mice. 18 The present study demonstrates that VLDL CIII ϩ and LDL CIII ϩ , components of RLPs, activate ␤1-integrin in THP-1 cells. Binding-blocking antibodies to ␤1-integrin or VCAM-1 abolished the increment of THP-1 cell adhesion induced by VLDL CIII ϩ , LDL CIII ϩ , or apoCIII. On apoCIII stimulation, THP-1 cell interaction with ECs under flow shifted from rolling to a firm adhesion phenotype, consistent with the action of ␤1-integrin. These results indicate that ␤1-integrin and its cognate ligand VCAM-1 play a dominant role in this process.
PKC plays an important role in several mechanisms that promote atherosclerosis. 22 PKC increases monocyte-endothelial interaction by modulating the expression and activation of integrins. 23 The PKC pathway includes the activation of Rho family proteins. 24 RhoA is one of the most important molecules regulating the actin cytoskeleton, integrins, and monocyte-endothelial interaction. 16 The present study showed that RhoA activation by VLDL CIII ϩ , LDL CIII ϩ , or apoCIII itself depends on PKC␣ activation. However, the effects of inhibiting RhoA on THP-1 cell adhesion and ␤1-integrin activation by apoCIII were smaller than inhibiting PKC␣. Thus, PKC␣ activation may activate PKC␣-dependent and RhoA-dependent and -independent signal transduction, leading to adhesion.
How apoCIII activates PKC␣ in THP-1 cells remains unclear. PKC␣, one of the conventional PKC isoforms, is activated by Ca 2ϩ , phospholipids, and diacylglycerol. 22 However, little information exists on possible direct effects of apoCIII on signal transduction in vascular cells and other type of cells. A recent study reported that apoCIII induces apoptosis of pancreatic ␤ cells by increasing intracellular Ca 2ϩ concentration, a potential activator of PKC␣. However, the study did not determine whether this led to the activation of PKC. 25 The exact mechanism(s) for apoCIII-induced PKC activation in THP-1 cells require further investigation.
VLDL CIII ϩ and LDL CIII ϩ compared with VLDL CIII Ϫ and LDL CIII Ϫ are enriched with lipids and apolipoproteins. 19 Lipids extracted from these fractions did not increase THP-1 cell adhesion or activate PKC␣. Lipids from LDL CIII ϩ activated PKC␦, but this did not cause adhesion. Thus, the lipids in apoCIII-containing lipoproteins do not play a role in adhesion but may affect other processes in monocytic cells that are dependent on PKC␦.
ApoCIII also resides on HDL particles. 5, 7 In contrast to apoB lipoproteins with apoCIII, HDL with apoCIII did not increase THP-1 cell adhesion. Some HDL preparations can inhibit integrin and adhesion molecule expression in leukocytes and ECs and reduce their adhesive interaction. 26, 27 Our current data suggest that one property of "antiinflammatory" HDL may be reduced apoCIII content. Inhibition of adhesion by HDL apoCIII Ϫ was more prominent under static than shear flow conditions. Because HDL apoCIII ϩ did not reduce adhesion, apoCIII may have counteracted potentially protective actions of other HDL components. Several studies reported that apoCIII in HDL associates with CHD at least in univariate analysis, 28, 29 and apoCIII in HDL has positive rather than inverse correlations with other risk factors such as VLDL and triglycerides. 7 Whether apoCIII affects antiatherogenic properties of HDL requires further study.
In conclusion, VLDL and LDL that contain apoCIII increase THP-1 cell adhesion to ECs via PKC-and RhoAmediated ␤1-integrin activation. ApoCIII itself caused these potentially proatherogenic effects. These results indicate that elevated levels of VLDL CIII ϩ and LDL CIII ϩ contribute to monocyte recruitment on vascular endothelium and suggest that apoCIII promotes atherosclerosis not only by impairing the catabolism of apoB lipoproteins but also by these direct mechanisms on vascular wall cells. Many previous studies have focused on the roles of lipid moieties such as oxidized lipids in the atherogenicity of apoB lipoproteins. Our observations provide novel insights into a role for apoCIII as a distinct contributor to inflammation and atherosclerosis.
